$BTAX
Biostax Corp. Stock $btax

$btax Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014710 Filed on April 16, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$288.5K	$268.0K	$957.1K
YoY Change	15.9%	5.24%	-16.72%
% of Gross Profit
Research & Development	$11.58K	$65.87K	$473.5K
YoY Change	-93.39%	362.57%	3226.27%
% of Gross Profit
Depreciation & Amortization	$0.00	$13.78K	$54.31K
YoY Change	-100.0%
% of Gross Profit
Operating Expenses	$300.0K	$293.3K	$1.485M
YoY Change	-31.41%	9.09%	27.63%
Operating Profit	-$300.0K		-$1.485M
YoY Change	-31.41%		27.63%
Interest Expense	-$127.9K	-$48.11K	$125.6K
YoY Change	-291.61%	261.73%	4.32%
% of Operating Profit
Other Income/Expense, Net	-$127.9K	$0.00	-$165.6K
YoY Change	91.6%		-93.02%
Pretax Income	-$428.0K	-$341.5K	-$1.651M
YoY Change	-15.13%	22.41%	-53.32%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$428.0K	-$341.5K	-$1.651M
YoY Change	-15.13%	22.41%	-53.32%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01		-$0.02
Diluted Earnings Per Share	-$0.01	$0.00	-$0.02
COMMON SHARES
Basic Shares Outstanding	83.74M shares	83.66M shares	83.51M shares
Diluted Shares Outstanding	83.70M shares		85.13M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	-$50.00	$29.79K	$29.79K
YoY Change	-100.29%	-80.2%	-80.2%
Cash & Equivalents	$5.451K	$29.79K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	-$49.00	$29.79K	$29.79K
YoY Change	-100.28%	-80.21%	-80.2%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.500K	$5.500K	$5.500K
YoY Change	0.0%	-89.16%	-89.16%
Total Long-Term Assets	$5.500K	$713.7K	$713.7K
YoY Change	-99.26%	-12.24%	-12.24%
TOTAL ASSETS
Total Short-Term Assets	-$49.00	$29.79K	$29.79K
Total Long-Term Assets	$5.500K	$713.7K	$713.7K
Total Assets	$5.451K	$743.5K	$743.5K
YoY Change	-99.28%	-22.85%	-22.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.256M	$1.351M	$1.351M
YoY Change	-7.65%	3.89%	3.89%
Accrued Expenses	$418.1K	$136.1K	$624.4K
YoY Change	207.27%	0.0%	16.38%
Deferred Revenue
YoY Change
Short-Term Debt	$2.602M	$2.289M	$2.289M
YoY Change	48.98%	109.73%	109.73%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.308M	$4.559M	$4.559M
YoY Change	37.48%	31.12%	31.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.308M	$4.559M	$4.559M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$5.308M	$4.559M	$4.559M
YoY Change	37.48%	31.12%	31.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$386.1M	-$384.6M
YoY Change	0.58%	0.43%
Common Stock	$380.8M	$380.8M
YoY Change	0.01%	0.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.303M	-$3.816M	-$3.816M
YoY Change
Total Liabilities & Shareholders Equity	$5.451K	$743.5K	$743.5K
YoY Change	-99.28%	-22.85%	-22.85%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$428.0K	-$341.5K	-$1.651M
YoY Change	-15.13%	22.41%	-53.32%
Depreciation, Depletion And Amortization	$0.00	$13.78K	$54.31K
YoY Change	-100.0%
Cash From Operating Activities	$18.38K	-$88.07K	-$656.5K
YoY Change	-105.85%	-121.22%	12.84%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-20.53K	113.3K	$535.8K
YoY Change	-106.93%	126.66%	-27.44%
NET CHANGE
Cash From Operating Activities	18.38K	-88.07K	-$656.5K
Cash From Investing Activities		0.000
Cash From Financing Activities	-20.53K	113.3K	$535.8K
Net Change In Cash	-2.150K	25.26K	-$120.7K
YoY Change	-87.76%	-172.27%	-64.85%
FREE CASH FLOW
Cash From Operating Activities	$18.38K	-$88.07K	-$656.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2022	us-gaap	Gross Profit GrossProfit		usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001559356
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi		usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi		usd
CY2023Q4	BTAX	Stock Issuances Due StockIssuancesDue		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2023	us-gaap	Gross Profit GrossProfit		usd
CY2022	BTAX	Research And Development Expense1 ResearchAndDevelopmentExpense1		usd
CY2023	BTAX	Gain On Issuance Of Forte License GainOnIssuanceOfForteLicense		usd
CY2023	BTAX	Receipt Of Common Shares ReceiptOfCommonShares		usd
CY2022	BTAX	Receipt Of Common Shares ReceiptOfCommonShares		usd
CY2023	BTAX	Change In Market Value Of Common Shares ChangeInMarketValueOfCommonShares		usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	BTAX	Common Stock Issued For Extension Of Patent And License Agreement CommonStockIssuedForExtensionOfPatentAndLicenseAgreement		usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2023	BTAX	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement		usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023	BTAX	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	BTAX	Increase Decrease In License Fees Payable IncreaseDecreaseInLicenseFeesPayable		usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities		usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	BTAX	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances		usd
CY2023	BTAX	Reclassification To Notes Payable From Accrued Interest ReclassificationToNotesPayableFromAccruedInterest		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodExercisePrice
CY2022	BTAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAveragePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodExercisePrice
CY2023	BTAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAveragePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	BTAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodExercisePrice
CY2023	BTAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAveragePrice
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	BTAX
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	11000000.0	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83738939	shares
CY2023	dei	Auditor Name AuditorName	Turner, Stone & Company LLP
CY2023	dei	Auditor Location AuditorLocation	Dallas, TX
CY2023	dei	Auditor Firm AuditorFirmId	76
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29785	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150491	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	29785	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	150491	usd
CY2023Q4	BTAX	Patents And Licenses PatentsAndLicenses	708192	usd
CY2022Q4	BTAX	Patents And Licenses PatentsAndLicenses	762500	usd
CY2023Q4	us-gaap	Deposits Assets DepositsAssets	5500	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	50728	usd
CY2023Q4	us-gaap	Assets Assets	743477	usd
CY2022Q4	us-gaap	Assets Assets	963719	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1350984	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1300366	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	336002	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	336002	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1183978	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	696478	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	152315	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	64455	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	136057	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	136057	usd
CY2023Q4	BTAX	License Fees Payable Current LicenseFeesPayableCurrent	295230	usd
CY2022Q4	BTAX	License Fees Payable Current LicenseFeesPayableCurrent	549079	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4559159	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3477173	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4559159	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3477173	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83657853	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83657853	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83045857	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83045857	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8366	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8305	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380795003	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380436432	usd
CY2022Q4	BTAX	Stock Issuances Due StockIssuancesDue	10303	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384619050	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-382968494	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3815682	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	743477	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	963719	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	957114	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1149257	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	473528	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14236	usd
CY2023	BTAX	Research And Development Expense1 ResearchAndDevelopmentExpense1	54308	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1484950	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1163493	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1484950	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1163493	usd
CY2022	BTAX	Gain On Issuance Of Forte License GainOnIssuanceOfForteLicense	3165151	usd
CY2023	us-gaap	Interest Expense InterestExpense	125607	usd
CY2022	us-gaap	Interest Expense InterestExpense	120403	usd
CY2022	BTAX	Change In Market Value Of Common Shares ChangeInMarketValueOfCommonShares	2645000	usd
CY2023	BTAX	Loss Gain On Settlement Of Obligations And Conversion Of Debt LossGainOnSettlementOfObligationsAndConversionOfDebt	-40000	usd
CY2022	BTAX	Loss Gain On Settlement Of Obligations And Conversion Of Debt LossGainOnSettlementOfObligationsAndConversionOfDebt	-1166418	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1605913	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-165607	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2372583	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1650557	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3536076	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83510001	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36290359	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85129597	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36290359	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7948256	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6283168	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	723324	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1605913	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	95973	usd
CY2022	BTAX	Stock Issued During Period Value Issued For Intangible Assets StockIssuedDuringPeriodValueIssuedForIntangibleAssets	262500	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3536076	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	48329	usd
CY2023	BTAX	Stock Issued During Period Value Issued For Intangible Assets StockIssuedDuringPeriodValueIssuedForIntangibleAssets	300000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1650557	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3815682	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3815682	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1650557	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3536076	usd
CY2023	BTAX	Common Stock Issued For Extension Of Patent And License Agreement CommonStockIssuedForExtensionOfPatentAndLicenseAgreement	300000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54308	usd
CY2022	BTAX	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement	3165151	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2645000	usd
CY2022	BTAX	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	-1166418	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1605913	usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-45228	usd
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	50728	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	50618	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	388539	usd
CY2023	BTAX	Increase Decrease In License Fees Payable IncreaseDecreaseInLicenseFeesPayable	-253849	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4620	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	87860	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	130229	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-75321	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	709858	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	304736	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-656534	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-581821	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-500000	usd
CY2022	BTAX	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances	6369	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	100000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	417058	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	435828	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	315000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	535828	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	738427	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-120705	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-343394	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	150491	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	493885	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29786	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	150491	usd
CY2022	BTAX	Reclassification To Notes Payable From Accrued Interest ReclassificationToNotesPayableFromAccruedInterest	7006492	usd
CY2023	BTAX	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	42703	usd
CY2022	BTAX	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	95973	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	262500	usd
CY2023Q4	us-gaap	Cash Cash	29785	usd
CY2023Q4	BTAX	Working Capital WorkingCapital	4529374	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384619050	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1650557	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zZbOcciuRVba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zUc14xzeSUua">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zS1v3ZEdzab2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_ztzivCX6Dy15">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z8CdEihWPiGl" title="Cash at federal deposit">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_84F_eus-gaap--DerivativesReportingOfDerivativeActivity_zADA3pYHeO91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zLi3tcosKtWi">Derivative Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 815, Fair Value Measurements requires bifurcation of certain embedded derivative instruments in certain debt or equity instruments, and measurement at their fair value for accounting purposes. A holder redemption feature embedded in the Company’s note payable requires bifurcation from its host instrument and is accounted for as a freestanding derivative. The Company held no derivative financial instruments at December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	473528	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14236	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	31995	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1619596	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1650557	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3536076	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83510001	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36290359	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1183978	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	696478	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	152315	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	64455	usd
CY2023	BTAX	Loss Gain On Settlement Of Obligations And Conversion Of Debt LossGainOnSettlementOfObligationsAndConversionOfDebt	-40000	usd
CY2022	BTAX	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	-1166418	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83657853	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83045857	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31995	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	20057162	shares
CY2021Q4	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	5.21
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	2293667	shares
CY2022	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAveragePrice	205.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	17725000	shares
CY2022	BTAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodExercisePrice	0.05
CY2022	BTAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAveragePrice	0.05
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	38495	shares
CY2022Q4	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	59.42
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	6500	shares
CY2023	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAveragePrice	73.85
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	31995	shares
CY2023Q4	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	56.49
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	91900000	usd
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	2033
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	27,226,000 will be limited to 80% of taxable income but will not expire
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19423000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19423000	usd
CY2023Q4	BTAX	Deferred Tax Assets Temporary Difference DeferredTaxAssetsTemporaryDifference	893000	usd
CY2022Q4	BTAX	Deferred Tax Assets Temporary Difference DeferredTaxAssetsTemporaryDifference	893000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18530000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18530000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18530000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18530000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.172	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.172	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.253	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.253	pure
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	200000	usd
CY2023	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-07-19
CY2023Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0600	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.215	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.215	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.000	pure
CY2023	BTAX	Cash Payment Description CashPaymentDescription	In consideration for the license, the Company will provide (i) a non-refundable cash payment of $500,000 within ninety (90) days of September 30, 2022, (ii) a non-refundable cash payment of $500,000 at the earliest of either the National Agency for Food and Drug Administration and Control (“NAFDAC”) approval for JKB-122 in Africa for any indication, or the enrollment of the first patient in a Food and Drug Administration (“FDA”) trail for Crohn’s Disease, (iii) 250,000 shares of common stock of the Company within sixty (60) days of September 30, 2022, (iv) an annual payment of $100,000 each anniversary of the date of the agreement until the Company gains regulatory approval in Africa, (v) milestone payments (described below), and (vi) royalties on net sales. The 250,000 shares of common stock represent approximately 0.32% of the currently outstanding common stock of the Company.
CY2023	BTAX	Description For Monthly Interest For Payment DescriptionForMonthlyInterestForPayment	the payment amount will bear the lower of (i) 1.5% interest per month or (ii) the maximum rate allowed by law, to be compounded quarterly. The interest will accrue beginning on the first day after the payment is due.
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000	usd
CY2023Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	100000	usd
CY2023	us-gaap	Debt Instrument Description DebtInstrumentDescription	The third note is for the principal amount of $200,000. Each of the three notes: (a) matures on July 19, 2023, with the Company having the option to extend the maturity date by six months (b) carries a six percent (6.00%) per annum simple interest rate; (c) provides that, if converted by the holder in accordance with its terms, the Company shall issue a number of shares of common stock in the Company to the holder of the note equal to (i) the principal amount of the note divided by (ii) $0.05, subject to certain equitable adjustments; and (d) requires the note holder to notify the Company in writing by 11:59 p.m. on July 22, 2022, the expiration of the conversion provision in each note; of its intent to exercise its conversion right. If converted into shares of common stock, each of the three notes prohibits the note holder, without the prior written consent of the Company, from selling, pledging, or otherwise transferring such shares for one year from their date of issuance, except that up to 5% of the shares may be sold, pledged, or otherwise transferred during three of every four calendar quarters during the 18-month period following the issuance date of the converted Note.
CY2023Q4	us-gaap	Share Price SharePrice	0.05
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	200000	usd
CY2023	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	2500000	shares

Files In Submission

Name	View Source	Status
0001493152-24-014710-index-headers.html	Edgar Link	pending
0001493152-24-014710-index.html	Edgar Link	pending
0001493152-24-014710.txt	Edgar Link	pending
0001493152-24-014710-xbrl.zip	Edgar Link	pending
btax-20231231.xsd	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex10-6_001.jpg	Edgar Link	pending
ex10-6_002.jpg	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex10-7_001.jpg	Edgar Link	pending
ex10-7_002.jpg	Edgar Link	pending
ex10-7_003.jpg	Edgar Link	pending
ex10-7_004.jpg	Edgar Link	pending
ex10-7_005.jpg	Edgar Link	pending
ex10-7_006.jpg	Edgar Link	pending
ex10-7_007.jpg	Edgar Link	pending
ex10-7_008.jpg	Edgar Link	pending
ex10-7_009.jpg	Edgar Link	pending
ex10-7_010.jpg	Edgar Link	pending
ex10-7_011.jpg	Edgar Link	pending
ex10-7_012.jpg	Edgar Link	pending
ex10-7_013.jpg	Edgar Link	pending
btax-20231231_def.xml	Edgar Link	unprocessable
btax-20231231_lab.xml	Edgar Link	unprocessable
btax-20231231_pre.xml	Edgar Link	unprocessable
ex10-7_014.jpg	Edgar Link	pending
ex10-7_015.jpg	Edgar Link	pending
ex10-7_016.jpg	Edgar Link	pending
ex10-7_017.jpg	Edgar Link	pending
ex10-7_018.jpg	Edgar Link	pending
ex10-7_019.jpg	Edgar Link	pending
ex14-1.htm	Edgar Link	pending
ex14-1_001.jpg	Edgar Link	pending
ex14-1_002.jpg	Edgar Link	pending
ex14-1_003.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
btax-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTAX
Biostax Corp. Stock $btax

2024 Q2 Form 10-K Financial Statement

#000149315224014710 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX Biostax Corp. Stock $btax

2024 Q2 Form 10-K Financial Statement

#000149315224014710 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX
Biostax Corp. Stock $btax